Hyperlipidemia in dialysis patients: What treatment?

Mineral and Electrolyte Metabolism

Volumn 23, Issue 3-6, 1997, Pages 311-313

  Iorio, Luigi ^a   Saltarelli, Giuseppe ^a   Nacca, Remo G ^a   Simonelli, Roberto ^a   Violi, Fabio ^a  

^a G De Bosis Hospital   (Italy)

Author keywords

Biocompatibility; Dialytic techniques; High flux membranes; Hyperlipidemia; Maintenance dialysis; Omega 3 fatty acids

Indexed keywords

CHOLESTEROL; CUPROPHANE; HEMOPHAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLYAMIDE; POLYSULFONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIOFILTRATION; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS MEMBRANE; DIET; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOFILTRATION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR;

FATTY ACIDS, OMEGA-3; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; INCIDENCE; RENAL DIALYSIS; RISK FACTORS;

EID: 0030662203     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Grundy SM: Management of hyperlipidemia of kidney disease. Kidney Int 1990;37:847-853.
2. Deferrari G, Fiorini F: Disordini del metabolismo e della nutrizione nell'uremia cronica; in Cambi V (ed): Trattato Italiano Dialisi, vol 2. Milano, Wichtig, 1990, pp 5-7.
3. Sakhrani L: Lipoprotein abnormalities in uraemia; in Nissenson AR, Fine RN, Gentile DE (eds): Clinical Dialysis. Appleton Contury-Crofts, Norwalk, Conn, 1984, pp 439-450.
4. Attman P, Alaupovic P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991;39(suppl 31):16-23.
5. Ma KW, Greene EI, Raij L: Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992;6:505-513.
6. Rostand SG, Brunzell JD, Cannon RO, Victor RG: Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;6:1053-1062.
7. Kaysen GA: Hyperlipidemia of chronic renal failure. Blood Purif 1994;12:60-67.
8. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989;ii:757-761.
9. Pierides AM, Alvarez-Ude F, Kerr DNS: Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet 1975;ii:1279-1282.
10. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatingemfibrozil combination therapy. JAMA 1990;264:71-75.
11. Jones PH, Patsch J, Gotto AM Jr: Biochimica della regolazione lipidica e valutazione delle dislipidemie; in Hurst JW (ed): Il Cuore, vol 2, Milano, McGraw-Hill, 1995, pp 1055-1070.
12. Docci D, Capponcini C, Mengozzi S, Baldrati L, Neri L, Feletti C: Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients. Nephron 1995;69:323-326.
13. Blankestijn PJ, Vos PF, Rabelink TJ, Van Rijn HJ, Jansen H, Koomans HA: High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1073-1078.